Mydecine's Mission is to Become a Trusted Source of Safe and Effective Medication-based Treatments to Address the Unmet Needs for Mental Health and Addiction Disorders

Mydecine – Medicine Evolved

Mydecine Innovations Group (NEO: MYCO) (OTC:MYCOF) (FSE:0NFA) is a biotechnology and digital technology company developing innovative second and third-generation novel compounds for the treatment of mental health and addiction through world-class technology and drug development infrastructure. The company's world-renowned medical and scientific advisory board is progressing a robust research and development (R&D) pipeline of psychedelic derived therapeutics, novel compounds, therapies, and controlled drug delivery systems.

Learn About Mydecine

Vertically Integrated

IP & Drug Development

We have submitted multiple pending patents for novel innovation in novel first- and second-generation drugs with a focus on safety and efficacy combined with an expert leadership team and leading research facilities in Canada and the United States.

Discover the Potential

Clinical Trial Development

We’re offering a robust clinical trial calendar spanning the globe focused on PTSD for veterans, EMS, and front-line workers, smoking cessation and substance-abuse disorders.

View Clinical Trials


Technology is a key component of our overall business strategy. Not only are we leveraging artificial intelligence and machine learning to inform our drug discovery process, we also built a virtual health platform tailored for psychedelics and inner wellness.

Discover Our Technology

Stock Information

Mydecine Innovations Group Inc.